Get the Stockscreener App
1.60
6.67%
0.10
Erasca Inc stock is traded at $1.60, with a volume of 1.02M.
It is up +6.67% in the last 24 hours and down -4.76% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.50
Open:
$1.52
24h Volume:
1.02M
Relative Volume:
0.92
Market Cap:
$453.87M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.9512
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-2.44%
1M Performance:
-4.76%
6M Performance:
+13.48%
1Y Performance:
-41.61%
1-Day Range:
$1.51
$1.64
1-Week Range:
$1.44
$1.6801
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.60 | 434.02M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Will Erasca Inc. Bounce From 52 Week LowWeekly Stock Analysis & Consistent Profit Trading Strategies - classian.co.kr
Technical Charts Suggest Momentum Shift in Erasca Inc.July 2025 Summary & Scalable Portfolio Growth Methods - Newser
How to escape a deep drawdown in Erasca Inc.July 2025 Reactions & Community Supported Trade Ideas - Newser
Relative strength of Erasca Inc. in sector analysisMarket Trend Report & Verified Stock Trade Ideas - Newser
Published on: 2025-08-20 02:52:23 - Newser
Will Erasca Inc. stock go up soonPortfolio Gains Report & Reliable Breakout Stock Forecasts - Newser
Candlestick signals on Erasca Inc. stock todayMarket Sentiment Review & Technical Entry and Exit Alerts - Newser
Erasca Inc. stock volume spike explainedJuly 2025 Fed Impact & Weekly Setup with ROI Potential - Newser
Is it time to cut losses on Erasca Inc.Market Performance Recap & Smart Swing Trading Alerts - Newser
Risk adjusted return profile for Erasca Inc. analyzedJuly 2025 Sentiment & Accurate Buy Signal Notifications - Newser
How to track smart money flows in Erasca Inc.July 2025 Earnings & Trade Opportunity Analysis - Newser
Is Erasca Inc. stock entering bullish territoryDay Trade & Real-Time Stock Price Movement Reports - Newser
Erasca Inc (ERAS Stock: A Sea of Opportunity - investchronicle.com
Erasca (NASDAQ:ERAS) Receives Equal Weight Rating from Morgan Stanley - Defense World
Market reaction to Erasca Inc.’s recent newsQuarterly Growth Report & Verified Trade Idea Suggestions - Newser
Should you wait for a breakout in Erasca Inc.2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Traders Watching For Reversal Pattern in Erasca Inc.2025 Performance Recap & Low Drawdown Trading Strategies - 선데이타임즈
Erasca's Strategic Reprioritization and Pipeline Delays: A Cautionary Tale for Biotech Investors - AInvest
Erasca Shares Fall After Downgrade From Morgan Stanley - MarketScreener
Erasca, Inc. shares fall 1.52% intraday after Morgan Stanley downgrades to Equalweight. - AInvest
Morgan Stanley Downgrades Erasca to Equalweight From Overweight, Cuts Price Target to $2 From $4 - MarketScreener
Research Analysts Issue Forecasts for Erasca FY2025 Earnings - Defense World
Predicting Erasca Inc. trend using moving averagesEarnings Risk Summary & Expert Curated Trade Ideas - Newser
Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data By Investing.com - Investing.com South Africa
Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data - Investing.com Australia
Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data - TipRanks
Is Erasca Inc. stock ready for a breakout2025 Key Highlights & Weekly Setup with ROI Potential - Newser
Can Erasca Inc. keep up with sector leaders2025 Momentum Check & AI Enhanced Trading Alerts - classian.co.kr
Is it too late to sell Erasca Inc.Weekly Gains Report & Consistent Profit Alerts - Newser
What technical models suggest about Erasca Inc.’s comeback2025 Price Momentum & Verified Swing Trading Watchlists - Newser
Technical analysis overview for Erasca Inc. stockNew Guidance & Real-Time Market Trend Scan - Newser
Erasca Inc. Recovers — But Is It SustainableJuly 2025 Fed Impact & Safe Capital Investment Plans - metal.it
Erasca (NASDAQ:ERAS) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Will Erasca Inc. stock recover after earningsWeekly Trade Analysis & Fast Moving Trade Plans - 선데이타임즈
When is the best time to exit Erasca Inc.July 2025 Snapshot & Daily Profit Maximizing Tips - Newser
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):